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Abstract
Although surgical excision is the standard of therapy for small renal masses (SRMs), there is a growing recognition of active
surveillance as an option in select patients who are poor surgical candidates or who have shorter life expectancy. A number of
patients on expectant management, however, subsequently advance to deﬁnitive therapy. In this study, we systematically reviewed
the literature and performed a pooled analysis of active surveillance series to evaluate the rate and indications for
deﬁnitive treatment after initiating a period of active surveillance. Fourteen clinical series (1245 patients; 1364 lesions) met our
selection criteria. Mean lesion size at presentation was 2.30 ± 0.40 cm with a mean follow-up of 33.6 ± 16.9 months. Collectively,
34.0% of patients underwent delayed intervention, which ranged in individual series from 3.6% to 70.3%. Of patients undergoing
delayed intervention, the average time on active surveillance prior to deﬁnitive treatment was 27.8 ± 10.6 months. A pooled
analysis revealed that 41.0% of patients underwent therapy secondary to tumor growth rate and 51.9% secondary to patient or
physician preference in the absence of clinical progression. Overall, 1.1% of all patients progressed to metastatic disease during
the average follow-up period. Thus, active surveillance may be an appropriate option for carefully selected patients with
SRMs. However, delayed treatment is pursued in a signiﬁcant percentage of patients within 3 years. Prospective registries and
clinical trials with standardized indications for delayed intervention are needed to establish true rates of disease progressions
and recommendations for delayed intervention.
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Introduction
The presentation of a patient with a small, incidentally found
renal lesion (<4 cm) is now a common clinical encounter for
practicing urologists. Due to the increased use of diagnostic
cross-sectional imaging, small renal masses (SRMs) are
being identiﬁed with greater frequency and now account for
48%–66% of renal cell carcinoma (RCC) diagnoses (1). This
has led to an increased incidence of RCC during the last
three decades and a concurrent increase in the rates of surgical
intervention (2, 3). Despite earlier diagnosis and treatment,
however, there has not been a signiﬁcant increase in cancer-
speciﬁc survival (CSS) or overall survival (OS) for patients
with SRMs (2–5).
For clinically localized SRMs, current treatment options
include surgical excision, ablation, and/or active surveillance
(AS) based on emerging evidence demonstrating equivalent,
short- and intermediate-term cancer-speciﬁc outcomes among
these modalities (2). Survival following surgical excision is
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well established with 5-year CSS rates over 95% following
partial or radical nephrectomy for patients with pT1a lesions
(4, 6). Although a number of ablative technologies have
emerged as potential treatment options, data on the long-
term effectiveness of these ablative techniques as valid alter-
natives to surgery have yet to be clearly demonstrated (2).
Recent studies have suggested CSS survival rates approach-
ing those achieved with surgical excision; however, the
majority of the series evaluating these techniques have
enrolled too few patients and employed disparate follow-up
protocols to yield meaningful conclusions (7).
While surgical therapy remains the cornerstone of treat-
ment for SRMs, the role of AS has also gained acceptance
as an option for select patients. These patients may be poor
surgical candidates due to age or competing health risks, or
they may be unwilling to accept the risks associated with
surgical management (3, 8). Poor performance status may
limit their ability to handle the physiologic stress of surgery,
and preexisting medical comorbidities such as cardiovascular
disease and chronic kidney disease may attenuate the survival
beneﬁt rendered by surgical intervention. In addition, recent
studies have shown that patients over 75 years of age are
more likely to die of cardiovascular and other non-cancerous
comorbidities than their clinically localized renal mass (3, 8, 9).
Use of AS has become more palatable in part from a
greater understanding of the biology of localized renal
tumors. While the natural history of SRMs is heterogeneous,
multiple studies have found that the majority of tumors under
AS demonstrate a slow interval growth and have a low rate of
metastatic progression (5, 10, 11). A meta-analysis of nine
recent AS series revealed a mean growth rate of 0.28 cm/
year in 234 observed tumors over a median follow-up of
32 months. While growth rates of conﬁrmed RCC lesions
varied considerably (rate 0.42 to 1.6 cm yearly), progression
to metastatic disease was identiﬁed in only 1% of lesions (12).
Of the patients who initiate AS, a notable subset will even-
tually undergo deﬁnitive treatment. Retrospective studies
have varied substantially in citing rates of patients who pro-
gress to delayed intervention (3.6%–70.2%) (13, 14). Data
regarding the reasons, timing, and indications for subsequent
deﬁnitive treatment after initiating a period of AS are hetero-
geneous and remain limited (12). In this article, we conse-
quently reviewed contemporary studies on AS of SRMs and
pooled data from individual series to evaluate the rate of and
indications for progression to delayed surgical intervention.
Materials and methods
We performed a literature search of English-language publi-
cations in the MEDLINE database to identify clinical studies
that reported AS of clinically localized SRMs from 1995 to
2016 using theNational Center for Biotechnology Information’s
PubMed site. Studies on SRMs that were clinically localized
at initial presentation were included. Series that included
metastatic RCC and those that did not differentiate the
growth rates of localized versus metastatic disease were
excluded from our study. Studies analyzing duplicate or pre-
viously studied populations were excluded. Furthermore,
case reports on the observation or treatment of single lesions
were excluded from analysis.
Pathological data from individual series were pooled to
evaluate the rate of and indications for delayed intervention.
Variables extracted included number of lesions, mean age of
presentation, mean tumor size (in cm), mean growth rate per
year (in cm per year), mean duration of AS, percentage of
patients who underwent delayed intervention, percentage of
solid versus cystic masses, and percent of metastatic progres-
sion. Overall weighted mean estimates were calculated for
these variables by combining data from individual series
with complete information. A further subset analysis was per-
formed to evaluate characteristics of lesions that were treated
with delayed intervention versus those that were kept on AS
protocol.
Results
Our systematic literature review yielded a total of 14 clinical
series of unique cohorts (Figure 1) that met our inclusion
criteria (1, 5, 10–22). Collectively, these studies accounted
for a total of 1245 lesions and 1364 patients. Themean number
of lesions followed in each study was 86 (median 55, range
15–240).A pooled analysis (Table 1) of cohort studies revealed
a mean age (± standard deviation) of 71.9 ± 3.9 years. Mean
tumor dimension at presentation was 2.30 ± 0.40 cm, and
among tumors for which pathologic data were available,
92.6% of lesions were characterized as solid and the remainder
were classiﬁed as Bosniak IV cysts. Overall, there was a mean
follow-up of 33.6 ± 16.9 months for all patients. Lesions had
a mean growth rate of 0.26 ± 0.16 cm per year (Figure 2).
Diagnostic biopsy was utilized in 21.8% of masses. Four of
14 studies provided quantiﬁable indications for selecting AS.
In sum, 34.0% of patients subsequently underwent delayed
intervention, and rates of delayed intervention in individual
series ranged from 3.6% to 70.3%. Overall, 1.1% of all patients
progressed to metastatic disease during the mean follow-up
period. Of the series with available outcome data, 11.9% of
patients died of any cause and 1.2% died of metastatic RCC.
Of patients undergoing delayed intervention, a subset
analysis of available data demonstrated the average time on
AS prior to deﬁnitive treatment was 27.75 ± 10.57 months.
Patients undergoing delayed intervention were generally
younger compared with other patients in AS (64.2 vs. 71.9
years old, respectively). The mean growth rate of tumors
that eventually underwent intervention was 0.70 ± 0.61 cm
per year (Figure 3). In comparison, tumors that remained
on AS demonstrated a mean growth rate of 0.28 ± 0.20 cm
per year. Twelve of 14 studies provided indications for
delayed therapy. Our pooled analysis revealed that 41.0%
of patients underwent therapy secondary to tumor growth
rate and 51.9% secondary to patient or physician preference
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in the absence of clinical progression. The remainder of
patients underwent therapy secondary to symptomatic pro-
gression. Of the series with available subset data, 29.9% of
patients who underwent delayed surgical intervention under-
went radical nephrectomy and 70.1% underwent a nephron-
sparing approach such as partial nephrectomy or thermal
ablation. Based on this subset, 8.3% of patients who under-
went delayed treatment died of any cause during the follow-
up period.
Discussion
Patients with clinical stage I renal masses have traditionally
undergone surgical removal with curative intent. The primary
goal of treating these often-incidental lesions has been to
provide oncologic control and alter the natural course of
the malignancy (10). Treatment of these lesions has not,
however, yielded a decrease in cancer-speciﬁc deaths from
RCC, suggesting the possible overtreatment of small, poten-
tially indolent renal tumors (3). Furthermore, there is grow-
ing recognition that competing risks from comorbidities in
elderly or inﬁrm patients may outweigh the survival beneﬁts
otherwise rendered by surgical intervention in patients with
localized renal tumors (8). For these reasons, AS of small
renal tumors is now a recognized option for patients who
have limited life expectancy (23).
Retrospective cohort studies have helped provide an under-
standing of the natural history of SRMs. Chawla et al. (12)
noted the risk of progression of SRMs to metastatic disease
while on AS was low (1%). Another meta-analysis by Kunkle
et al. (2) of 99 series and 6471 renal lesions managed with
surgery, ablation, or AS noted no statistical differences in
the incidence of metastatic progression regardless of how
tumors were managed. These results suggest that AS is a
safe treatment alternative for patients that are elderly or
have signiﬁcant, competing medical comorbidities.
Current data, however, suggest that delayed treatment
is pursued in a signiﬁcant percentage of patients within
3 years. Thresholds for termination of an AS protocol and
implementation of deﬁnitive intervention, however, are
unclear and not well deﬁned in the majority of published
series. Typically, the decision to proceed with delayed inter-
vention is based largely upon tumor growth rate or changes
in the radiographic characteristics of the tumor. In our pooled
analysis, an increase in tumor size was cited as the primary
reason for 41.01% of patients who underwent delayed inter-
vention. As our study reveals, mean observed tumor growth
rate was notably greater in patients who eventually underwent
delayed intervention compared with patients who remained
on surveillance (0.70 cm/year vs. 0.28 cm/year). This ﬁnding
suggests that a tumor’s observed growth kinetics can weigh
heavily upon physicians’ and patients’ decision to pursue
delayed intervention. It is unclear from current literature
whether tumor growth kinetics, however, are associated with
unfavorable biological activity, and a direct correlation is
yet to be demonstrated (12). Kunkle et al. (24), for example,
found that a substantial proportion (26%–33%) of renal
tumors exhibited zero radiographic growth over a median
29-month follow-up and reported similar rates of malignancy
compared with growing lesions. Recent studies have also
found that the rate of tumor growth has not been shown to pre-
dict malignant histology in tumors which do demonstrate
Figure 1. Study selection ﬂow diagram.
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interval growth (12, 21). Furthermore, a multicenter prospec-
tive study by Jewett et al. (16) also showed that histologically
proven benign tumors (e.g., angiomyolipoma and oncocy-
toma) appear to grow at the same rate as malignant ones.
Our study was unable to corroborate these ﬁndings due to
limitations of histologic data in our clinical series.
Our pooled analysis also revealed 51.9% of patients who
elected delayed intervention did so secondary to patient or
physician preference in the absence of clinical progression.
This was based largely upon patient or physician perceptions
of risk of remaining on AS or upon a change in a patient’s
medical clearance by his or her physician. In the absence of
curative treatment options for metastatic disease, patients
and physicians who elect AS assume a calculated risk of the
development of metastasis during or after the AS period
(18). Patient anxiety about disease progression and of poten-
tial limitations on available treatment options in the future
can consequently inﬂuence their decision to terminate AS.
Recent series, however, have suggested that a period of AS
followed by delayed primary intervention is not associated
with alterations in treatment plan or stage migration (5, 25).
Some authors have also shown that delaying intervention
on AS does not limit or compromise the feasibility of
nephron-sparing surgery nor does it lead to an increased
risk of local or metastatic progression (25, 26).
Limitations of our study stem from the predominantly
retrospective nature of the studies included in our analysis.
The majority of the studies had a short duration of follow-
up (mean 33.6 months) and provided little data on how AS
impacted patient quality of life. In addition, there was a
lack of uniform indications for initiating or terminating AS
among the studies included. One report included in our ana-
lysis was prospective in nature: Pierorazio et al. (27) recently
published the results from the multi-institutional delayed
intervention and surveillance for SRMS (DISSRM) registry
for 497 patients with SRMs who prospectively underwent
AS versus primary intervention (PI). Over a median follow-
up of 2.1 years, 9% of patients on AS underwent delayed
intervention. They found that AS was not inferior to PI for
a well-selected cohort of patients: OS for PI and AS was
98% and 96% at 2 years, and 92% and 75% at 5 years, respec-
tively (log rank, P = 0.06). At 5 years, CSS was 99% and
100% for PI and AS, respectively (P = 0.3). Of the patients
that underwent delayed intervention, 71% were elective or
Table 1. Retrospective studies of unique cohorts of small renal masses managed on active surveillance with available
pathologic data.
Study Year
Number of
patients/
SRMs
Mean age
(years)
Mean initial
tumor
dimension
(cm)
Mean
linear
growth rate
(cm/year)
Mean
surveillance
follow-up
(months)
Metastatic
progression
(%)
Delayed
intervention
(%)
Bosniak (14) 1995 37/40 66 1.73 0.36 39 0.0 70.3
Volpe (1) 2004 29/32 71 2.93 0.10 28 0.0 27.6
Wehle (17) 2004 29/29 70 1.83 0.12 32 0.0 31.0
Siu (21) 2006 47/47 68 2.00 0.27 29 2.0 29.8
Kouba (5) 2007 43/46 67 2.92 0.70 36 0.0 30.2
Matsuzaki (22) 2007 15/15 67 2.20 0.06 38 0.0 20.0
Youssif (18) 2007 35/44 72 2.20 0.24 48 5.7 22.9
Abouassaly (13) 2008 110/110 81 2.50 0.26 24 0.0 3.6
Crispen (10) 2009 154/172 69 2.50 0.29 31 1.3 44.2
Rosales (15) 2010 212/223 71 2.80 0.34 35 1.9 5.2
Jewett (16) 2011 178/209 73 2.10 0.26 28 1.1 12.9
Patel (19) 2011 71/93 72 2.20 0.21 34 1.4 19.7
Brunocilla (20) 2013 62/64 75 2.60 0.70 92 3.2 25.8
Pierorazio (25) 2015 223/240 71 1.90 0.11 25 0.0 9.4
Totals 1245/1364 71 2.30 ± 0.40 0.26 ± 0.16 33.6 ± 16.9 1.1 34.0
Bold font signiﬁes median values provided in the study.
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patient preference (growth rate 0.08 cm/year) and 29% were
due to growth rate >0.5 cm/year (mean growth rate 1.1 cm/
year). These results support the notion that patient concern
for disease progression plays a signiﬁcant role in the duration
of AS and decision to pursue delayed intervention. While this
study suggests that tumor growth rate during AS is a common
indication for terminating AS, data from the DISSRM
registry suggest that the number of patients terminating AS
due to tumor growth rate may be decreased by establishing
thresholds for intervention. Data from the DISSRM registry
also demonstrated that there was no difference in quality of
life assessments between patients undergoing AS versus pri-
mary intervention; AS of SRMs did not appear to negatively
impact patients’ quality of life or mental health (28).
Our study suggests that delayed surgical treatment is pur-
sued in a signiﬁcant percentage of patients within 28 months
Figure 2. Tumor dimension versus time on active surveillance. Line slopes represent mean growth rate in each series.
Figure 3. Tumor dimension versus time on active surveillance for patients undergoing delayed intervention versus those on active
surveillance. Line slopes represent mean growth rate in each series. Dashed line represents mean surveillance time.
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of initiating AS. While the risk to metastatic progression is
low, AS may not be a durable option for patients who are
acceptable surgical candidates or who have extended life
expectancies. AS should consequently only be used as alterna-
tive to deﬁnitive therapy in select patients who have limited
life expectancy or competing health risks that preclude sur-
gery. Appropriate patient counseling prior to initiating AS
is therefore paramount in establishing whether AS is a suita-
ble treatment modality for managing a patient’s SRM. If AS
for SRMs is to be established and widely adopted, thresholds
for terminating AS and implementing deﬁnitive intervention
need to be clearly identiﬁed. Additional data from long-
term prospective registries and clinical trials with standar-
dized indications for delayed intervention are needed to
establish AS as an effective management strategy for
SRMs. Furthermore, because clinical and radiographic char-
acteristics on patient presentation are poor predictors of
future growth rate, alternative measures for potential disease
progression are needed (29, 30). With this in mind, the routine
use of percutaneous renal mass biopsy has been suggested to
improve risk stratiﬁcation prior to initiating AS. However,
this approach has not been shown to improve patient treat-
ment selection or decrease the need for delayed intervention
in AS series.
Conclusion
AS may be an appropriate option for carefully selected
patients with SRMs. Current data, however, suggest that
delayed treatment is pursued in a signiﬁcant percentage of
patients within 3 years. Our pooled analysis reveals that in
addition to tumor growth rate, a signiﬁcant proportion of
patients undergo delayed surgical therapy due to patient pre-
ference or anxiety in the absence of clinical progression.
Additional data from long-term prospective registries and
clinical trials with standardized indications for delayed inter-
vention are needed to create a comprehensive AS protocol for
SRMs.
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